Comparing Genetically Engineered Mouse Mammary Cancer Models with Human Breast Cancer by Expression Profiling1

2007 ◽  
Vol 28 (1) ◽  
pp. 39-51 ◽  
Author(s):  
Alexander N. Shoushtari ◽  
Aleksandra M. Michalowska ◽  
Jeffrey E. Green
Keyword(s):  
Breast Cancer ◽  
Human Breast Cancer ◽  
Mammary Cancer ◽  
Genetically Engineered ◽  
Human Breast ◽  
Cancer Models

Abstract 950: Src tyrosine kinase contributes to lapatinib resistance in human breast cancer models.

2013 ◽  
Author(s):  
Roberta Rosa ◽  
Lucia Nappi ◽  
Luigi Formisano ◽  
Claudia D'Amato ◽  
Valentina D'Amato ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Tyrosine Kinase ◽  
Human Breast Cancer ◽  
Human Breast ◽  
Src Tyrosine Kinase ◽  
Cancer Models

Abstract 2260: Defining molecular mechanisms linking Endophilin A2 to metastasis in human breast cancer models

2015 ◽  
Author(s):  
Tomas Baldassarre ◽  
Kathleen Watt ◽  
Peter Truesdell ◽  
Mark Schneider ◽  
Sandip Sengupta ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Human Breast Cancer ◽  
Molecular Mechanisms ◽  
Human Breast ◽  
Cancer Models

scholarly journals Dissecting genetic requirements of human breast tumorigenesis in a tissue transgenic model of human breast cancer in mice

2009 ◽  
Vol 106 (17) ◽  
pp. 7022-7027 ◽  
Author(s):  
Min Wu ◽  
Lina Jung ◽  
Adrian B. Cooper ◽  
Christina Fleet ◽  
Lihao Chen ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Targeted Therapies ◽  
Human Breast Cancer ◽  
Cancer Biology ◽  
Genetic Alterations ◽  
Genetically Engineered ◽  
Human Breast ◽  
Breast Tumorigenesis ◽  
Preneoplastic Lesions

Breast cancer development is a complex pathobiological process involving sequential genetic alterations in normal epithelial cells that results in uncontrolled growth in a permissive microenvironment. Accordingly, physiologically relevant models of human breast cancer that recapitulate these events are needed to study cancer biology and evaluate therapeutic agents. Here, we report the generation and utilization of the human breast cancer in mouse (HIM) model, which is composed of genetically engineered primary human breast epithelial organoids and activated human breast stromal cells. By using this approach, we have defined key genetic events required to drive the development of human preneoplastic lesions as well as invasive adenocarcinomas that are histologically similar to those in patients. Tumor development in the HIM model proceeds through defined histological stages of hyperplasia, DCIS to invasive carcinoma. Moreover, HIM tumors display characteristic responses to targeted therapies, such as HER2 inhibitors, further validating the utility of these models in preclinical compound testing. The HIM model is an experimentally tractable human in vivo system that holds great potential for advancing our basic understanding of cancer biology and for the discovery and testing of targeted therapies.

Positive interaction between lapatinib and capecitabine in human breast cancer models: study of molecular determinants

2011 ◽  
Vol 26 (4) ◽  
pp. 530-537 ◽  
Author(s):  
Mohamed Chefrour ◽  
Gérard Milano ◽  
Patricia Formento ◽  
Sarah Giacometti ◽  
Amine Denden ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Human Breast Cancer ◽  
Human Breast ◽  
Positive Interaction ◽  
Cancer Models ◽  
Molecular Determinants

scholarly journals Initiating oncogenic event determines gene-expression patterns of human breast cancer models

2002 ◽  
Vol 99 (10) ◽  
pp. 6967-6972 ◽  
Author(s):  
K. V. Desai ◽  
N. Xiao ◽  
W. Wang ◽  
L. Gangi ◽  
J. Greene ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Gene Expression ◽  
Human Breast Cancer ◽  
Expression Patterns ◽  
Gene Expression Patterns ◽  
Human Breast ◽  
Cancer Models

Interferon in Breast Cancer

1977 ◽  
Vol 63 (2) ◽  
pp. 155-162 ◽  
Author(s):  
Eugenia S. De Lustig ◽  
Nuria Cortada De De La Peña ◽  
Abel Canonico
Keyword(s):  
Breast Cancer ◽  
Human Breast Cancer ◽  
Mammary Cancer ◽  
Inverse Correlation ◽  
Interferon Response ◽  
Normal Donor ◽  
Interferon Production ◽  
Human Breast ◽  
Remission Period

The interferon production ability by leukocytes in vitro from 37 patients with mammary cancer was studied. The leukocytes were derived from patients between 27 and 80 years of age, 6 months and up to 28 years after removal of the primary tumor. The interferon titer of 34/37 human breast cancer leukocytes was 2–8 times lower than that of 35 normal donor leukocytes and 3 non-neoplastic diseases. No correlation between interferon titers, the patient's age, and the histologic tumor features was observed; however, interferon production was observed to return to normal in those patients who had a long remission period or whose tumors were locally confined. Interferon response of patients under different therapy was modified: radiotherapy affected interferon production more severely than chemotherapy. A tendency for association between the skin DNCB test and interferon response was found. An inverse correlation was observed between interferon titers and the PHA-induced transformation index.

scholarly journals Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models

2014 ◽  
Vol 105 (10) ◽  
pp. 1334-1342 ◽  
Author(s):  
Yasuhiro Funahashi ◽  
Kiyoshi Okamoto ◽  
Yusuke Adachi ◽  
Taro Semba ◽  
Mai Uesugi ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Tumor Microenvironment ◽  
Vascular Remodeling ◽  
Human Breast Cancer ◽  
Human Breast ◽  
Eribulin Mesylate ◽  
Cancer Models

Antitumor activities of the synthetic retinoid ST1926 in two-dimensional and three-dimensional human breast cancer models

2017 ◽  
Vol 28 (7) ◽  
pp. 757-770 ◽  
Author(s):  
Patrick Aouad ◽  
Melody Saikali ◽  
Rana Abdel-Samad ◽  
Sabreen Fostok ◽  
Leeanna El-Houjeiri ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Human Breast Cancer ◽  
Three Dimensional ◽  
Two Dimensional ◽  
Human Breast ◽  
Antitumor Activities ◽  
Synthetic Retinoid ◽  
Cancer Models
Sign in / Sign up

Export Citation Format

Share Document